<a href=Boston Scientific” height=”230″ src=”https://www.medicaldevice-network.com/wp-content/uploads/static-progressive/nri/medicaldevice/news/April/boston.jpg” style=”padding: 10px” width=”301″ />

Boston Scientific has announced the US and European launch of Victory guidewire, designed to provide access to cross and treat resistant lesions.

Lesions are characterised by blockages in or narrowing of blood vessels in the peripheral vasculature, leading to various peripheral artery diseases including critical limb ischemia (CLI), in which patients have multi-vessel diseases and challenging lesions.

The Victory guidewire, which comes in both 0.014in and 0.018in diameters, uses the stainless-steel core technology to provide superior torque for optimal steering and control.

Boston Scientific peripheral interventions division president Jeff Mirviss said physicians treating CLI patients typically require a variety of treatment options and crossing solutions.

"Victory guidewires complement our already broad portfolio of crossing solutions, inclusive of our market-leading angioplasty balloons, Rubicon support catheter and the TruePath™ CTO device," Mirviss added.

"The Victory guidewires offer another option to cross these highly-resistant lesions and potentially avoid the need for amputation."

In addition, the guidewire has a hydrophilic coating that provides enhanced lubricity to facilitate crossing resistant lesions.

Spectrum Medical Group vascular and interventional radiology director and interventional radiologist Derek Mittleider said resistant lesions can be a challenge, requiring various tools to access, cross and treat.

"The Victory wire’s high gram-load options and excellent torque-ability give me the extra push and steer-ability I need to get through these resistant lesions more easily, making these cases less challenging," Mittleider added.

The company is planning to launch Victory guidewire in other international markets later this year and in 2013.

Image: Boston Scientific’s Corporate Headquarters in Natick, Massachusetts, US. Photo: courtesy of BostonScientific.